What's new? Log in Free sign up

Nuvalent (NUVL)

Company Profile

Company profile

Ticker

NUVL

Exchange

Website

www.nuvalent.com

CEO

Dr. James R. Porter Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Meat-Tech 3D Ltd., MeaTech 3D Ltd.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Nuvalent Securities Corporation ...

NUVL stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Restricted Stock Unit Award Agreement

Quarterly report

12 Nov 24

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Quarterly report

8 Aug 24

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Latest ownership filings

View all

James Richard Porter

Notice of proposed sale of securities

Henry E. Pelish

Deborah Ann Miller

Christopher Durant Turner

Alexandra Balcom

James Richard Porter

Notice of proposed sale of securities

Financial summary

Financial statements Chart NUVL financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	369.24 mm	369.24 mm	369.24 mm	369.24 mm	369.24 mm	369.24 mm
Cash burn (monthly)	(no burn)	(no burn)	28.10 mm	20.71 mm	15.27 mm	12.77 mm
Cash used (since last report)	n/a	n/a	113.03 mm	83.29 mm	61.43 mm	51.37 mm
Cash remaining	n/a	n/a	256.21 mm	285.96 mm	307.82 mm	317.87 mm
Runway (months of cash)	n/a	n/a	9.1	13.8	20.2	24.9

Beta Read what these cash burn values mean

Financial data from Nuvalent earnings reports.

Institutional ownership, Q3 2024

NUVL institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	197	175	+12.6%
Opened positions	50	30	+66.7%
Closed positions	28	35	-20.0%
Increased positions	73	68	+7.4%
Reduced positions	53	55	-3.6%

13F shares	Current	Prev Q	Change
Total value	6.99 tn	4.89 tn	+42.9%
Total shares	97.85 mm	93.56 mm	+4.6%
Total puts	619.30 k	131.30 k	+371.7%
Total calls	449.50 k	527.40 k	-14.8%
Total put/call ratio	1.4	0.2	+453.4%

Largest owners	Shares	Value	Change
Flynn James E	25.58 mm	$0.00	0.0%
Deerfield Management	19.99 mm	$2.05 tn	0.0%
FMR	9.65 mm	$987.64 bn	+8.9%
Paradigm Biocapital Advisors	5.00 mm	$511.50 bn	+9.4%
Vanguard	4.13 mm	$422.87 bn	+9.5%
BlackRock	3.62 mm	$370.84 bn	NEW
Perceptive Advisors	2.98 mm	$304.78 bn	+16.9%
Bain Capital Life Sciences Investors	2.70 mm	$275.93 bn	0.0%
Bain Capital Life Sciences Fund II	2.40 mm	$183.98 mm	0.0%
Fairmount Funds Management	1.69 mm	$172.59 bn	-12.3%

Largest transactions	Shares	Bought/sold	Change
BlackRock	3.62 mm	+3.62 mm	NEW
BLK BlackRock	0.00	-3.02 mm	EXIT
FMR	9.65 mm	+786.26 k	+8.9%
Commodore Capital	940.00 k	-547.76 k	-36.8%
Perceptive Advisors	2.98 mm	+430.16 k	+16.9%
Paradigm Biocapital Advisors	5.00 mm	+428.32 k	+9.4%
Wellington Management	1.01 mm	+400.40 k	+65.5%
Vanguard	4.13 mm	+357.61 k	+9.5%
Norges Bank	0.00	-332.68 k	EXIT
T. Rowe Price	1.08 mm	+328.14 k	+43.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NUVL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 25	Matthew Shair	Class A Common Stock	Sell	Dispose S	Yes	Yes	85	108	9.18 k	218,522
27 Jan 25	Matthew Shair	Class A Common Stock	Sell	Dispose S	Yes	Yes	83.88	234	19.63 k	218,630
27 Jan 25	Matthew Shair	Class A Common Stock	Sell	Dispose S	Yes	Yes	82.91	618	51.24 k	218,864
27 Jan 25	Matthew Shair	Class A Common Stock	Sell	Dispose S	Yes	Yes	82.24	1,040	85.53 k	219,482
15 Jan 25	James Richard Porter	Class A Common Stock	Sell	Dispose S	No	Yes	77.28	5,842	451.47 k	249,062
15 Jan 25	James Richard Porter	Class A Common Stock	Sell	Dispose S	No	Yes	76.65	5,493	421.04 k	254,904
15 Jan 25	James Richard Porter	Class A Common Stock	Sell	Dispose S	No	Yes	75.51	9,358	706.62 k	260,397
15 Jan 25	James Richard Porter	Class A Common Stock	Sell	Dispose S	No	Yes	74.94	6,307	472.65 k	269,755
15 Jan 25	James Richard Porter	Class A Common Stock	Option exercise	Acquire M	No	Yes	27.85	27,000	751.95 k	276,062
15 Jan 25	James Richard Porter	Stock Option Class A Common Stock	Option exercise	Dispose M	No	Yes	27.85	27,000	751.95 k	312,780

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Nuvalent, Maintains $110 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Nuvalent (NASDAQ:NUVL) with a Buy and maintains $110 price target.

Nuvalent Targets 2026 Approval With Accelerated NDA For Zidesamtinib In ROS1-Positive NSCLC

Strategy prioritizes most accelerated path to first potential approval Initial NDA submission expected by mid-year for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population, with topline pivotal data

This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

HC Wainwright & Co. Initiates Coverage On Nuvalent with Buy Rating, Announces Price Target of $110

Press releases

From Benzinga Pro

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Strategy prioritizes most accelerated path to first potential approval Initial NDA submission expected by mid-year for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population, with topline pivotal data

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,

Nuvalent Appoints Grant Bogle to Board of Directors

CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.